Detailed Tarceva Phase III NSCLC data

Partners OSI (OSIP), Genentech (DNA) and Roche (SWX:ROCZ) presented detailed data from a Phase III trial of Tarceva erlotinib in 731 patients with relapsed non-small cell lung cancer (NSCLC). In the international trial, Tarceva showed a 42.5% improvement in median survival and a 41% improvement in one-year survival rates compared with placebo. Tarceva patients had a median overall survival of 6.7 months compared with 4.7 months for placebo (p=0.001), the primary endpoint. In addition, 31% of Tarceva patients were alive at one year versus 22% of placebo patients. ...